Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 199.7	$ 223.6
Payments	64.1	83.2
Biocon Biologics Transaction	220.0
Accretion	8.2	9.0
Reclassifications	0.0	0.0
Fair value loss (gain)	11.2	50.3
Balance at end of period	375.0	199.7
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	66.7	100.5
Payments	64.1	83.2
Biocon Biologics Transaction	0.0
Accretion	0.0	0.0
Reclassifications	61.8	49.4
Fair value loss (gain)	0.0	0.0
Balance at end of period	64.4	66.7
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	133.0	123.1
Payments	0.0	0.0
Biocon Biologics Transaction	220.0
Accretion	8.2	9.0
Reclassifications	(61.8)	(49.4)
Fair value loss (gain)	11.2	50.3
Balance at end of period	$ 310.6	$ 133.0